The aim of this study was to determine several key metabolites as potential biomarkers of daunorubicin (DNR) treatment of acute promyelocytic leukemia (APL) using APL blasts and NB4 cells. Samples which were obtained from 16 newly diagnosed APL patients and human APL NB4 cell lines were exposed to increasing concentrations of DNR (0 μM, 0.1 μM, 0.5 μM and 1.0 μM). Electron microscopy and Nuclear Magnetic Resonance (NMR) spectroscopy confirmed that there were clear differences between controls and DNR-treated groups, with the resultant models having excellent predictive and discriminative abilities. Four metabolites meeting the biomarker requirements were identified. KEGG analyses revealed that these biomarkers were associated with the metabolism of fat, choline, and glucose. These findings offered vital information about the effects of chemotherapies on the whole body biochemistry which might be important for monitoring apoptosis and injury to cells in order to reduce chemotherapies-induced side effects.

这项研究的目的是确定使用APL母细胞和NB4细胞的几种主要代谢物，作为柔红霉素（DNR）治疗急性早幼粒细胞白血病（APL）的潜在生物标志物。从16名新诊断的APL患者和人类APL NB4细胞系中获得的样品暴露于浓度不断增加的DNR（0μM，0.1μM，0.5μM和1.0μM）。电子显微镜和核磁共振（NMR）光谱证实，对照组和DNR处理组之间存在明显差异，所得模型具有出色的预测和判别能力。确定了满足生物标志物要求的四种代谢物。KEGG分析显示，这些生物标志物与脂肪，胆碱和葡萄糖的代谢有关。